Emergent Biosolutions, Inc. (NYSE:EBS) Chairman Fuad El-Hibri sold 25,000 shares of the firm’s stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $38.50, for a total transaction of $962,500.00. Following the completion of the transaction, the chairman now directly owns 1,603,763 shares in the company, valued at approximately $61,744,875.50. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Fuad El-Hibri also recently made the following trade(s):

  • On Thursday, September 7th, Fuad El-Hibri sold 16,439 shares of Emergent Biosolutions stock. The stock was sold at an average price of $37.50, for a total transaction of $616,462.50.
  • On Tuesday, September 5th, Fuad El-Hibri sold 3,100 shares of Emergent Biosolutions stock. The stock was sold at an average price of $37.50, for a total transaction of $116,250.00.
  • On Thursday, August 31st, Fuad El-Hibri sold 5,461 shares of Emergent Biosolutions stock. The stock was sold at an average price of $37.50, for a total transaction of $204,787.50.
  • On Thursday, July 27th, Fuad El-Hibri sold 25,000 shares of Emergent Biosolutions stock. The stock was sold at an average price of $36.50, for a total transaction of $912,500.00.
  • On Thursday, July 20th, Fuad El-Hibri sold 25,000 shares of Emergent Biosolutions stock. The stock was sold at an average price of $35.50, for a total transaction of $887,500.00.

Emergent Biosolutions, Inc. (NYSE:EBS) traded down 0.14% on Thursday, reaching $38.10. 136,565 shares of the company traded hands. The stock has a market capitalization of $1.57 billion, a PE ratio of 24.26 and a beta of 1.23. Emergent Biosolutions, Inc. has a one year low of $24.47 and a one year high of $38.74. The firm has a 50 day moving average of $36.14 and a 200-day moving average of $32.54.

Emergent Biosolutions (NYSE:EBS) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $0.13 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.26 by ($0.13). Emergent Biosolutions had a net margin of 13.42% and a return on equity of 14.50%. The company had revenue of $100.77 million during the quarter, compared to the consensus estimate of $111.57 million. During the same quarter in the previous year, the company earned ($0.05) earnings per share. The business’s revenue was up 10.4% on a year-over-year basis. On average, analysts anticipate that Emergent Biosolutions, Inc. will post $1.54 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This article was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/09/14/insider-selling-emergent-biosolutions-inc-ebs-chairman-sells-25000-shares-of-stock.html.

A number of hedge funds have recently made changes to their positions in EBS. Louisiana State Employees Retirement System boosted its holdings in Emergent Biosolutions by 2.2% in the first quarter. Louisiana State Employees Retirement System now owns 14,100 shares of the biopharmaceutical company’s stock valued at $409,000 after acquiring an additional 300 shares during the last quarter. State of Alaska Department of Revenue boosted its holdings in Emergent Biosolutions by 2.7% in the first quarter. State of Alaska Department of Revenue now owns 3,820 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 100 shares during the last quarter. Great West Life Assurance Co. Can boosted its holdings in Emergent Biosolutions by 5.9% in the first quarter. Great West Life Assurance Co. Can now owns 47,682 shares of the biopharmaceutical company’s stock valued at $1,384,000 after acquiring an additional 2,649 shares during the last quarter. State Board of Administration of Florida Retirement System boosted its holdings in Emergent Biosolutions by 213.3% in the first quarter. State Board of Administration of Florida Retirement System now owns 67,106 shares of the biopharmaceutical company’s stock valued at $1,949,000 after acquiring an additional 45,688 shares during the last quarter. Finally, US Bancorp DE boosted its holdings in Emergent Biosolutions by 12.0% in the first quarter. US Bancorp DE now owns 40,985 shares of the biopharmaceutical company’s stock valued at $1,191,000 after acquiring an additional 4,398 shares during the last quarter. Institutional investors and hedge funds own 85.44% of the company’s stock.

Several research analysts recently weighed in on EBS shares. BidaskClub raised shares of Emergent Biosolutions from a “hold” rating to a “buy” rating in a research note on Friday, August 25th. Zacks Investment Research lowered shares of Emergent Biosolutions from a “hold” rating to a “sell” rating in a research note on Monday, July 17th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $44.00.

About Emergent Biosolutions

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Insider Buying and Selling by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.